NIH #3UM1CA186691-09S1
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
Active
- Amount
- $1.9M
- Period
- 2026-02-17 → 2027-02-28
- PIs
- 6
- Est. capacity / PI
- ~3 students
Awarded at JOHNS HOPKINS UNIVERSITY
NIH #5UM1CA186691-09
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
Active
- Amount
- $1.8M
- Period
- 2014-03-13 → 2027-02-28
- PIs
- 6
- Est. capacity / PI
- ~0 students
Awarded at JOHNS HOPKINS UNIVERSITY
NIH #5UM1CA186691-08
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
- Amount
- $1.7M
- Period
- 2014-03-13 → 2026-02-28
- PIs
- 6
- Est. capacity / PI
- ~0 students
Awarded at JOHNS HOPKINS UNIVERSITY
NIH #4UM1CA186691-07
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
- Amount
- $1.8M
- Period
- 2014-03-13 → 2026-02-28
- PIs
- 5
- Est. capacity / PI
- ~0 students
Awarded at JOHNS HOPKINS UNIVERSITY
NIH #2UM1CA186691-06
The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
- Amount
- $5.7M
- Period
- 2014-03-13 → 2023-02-28
- PIs
- 5
- Est. capacity / PI
- ~0 students
Awarded at JOHNS HOPKINS UNIVERSITY
NIH #5R01CA152303-05
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients
- Amount
- $299K
- Period
- 2010-07-02 → 2016-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #5R01CA152303-04
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients
- Amount
- $289K
- Period
- 2010-07-02 → 2015-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #5R01CA152303-03
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients
- Amount
- $308K
- Period
- 2010-07-02 → 2015-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #5R01CA152303-02
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients
- Amount
- $289K
- Period
- 2010-07-02 → 2015-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #1R01CA152303-01
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients
- Amount
- $298K
- Period
- 2010-07-02 → 2015-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #5R21CA135622-02
Evaluation of Src Inhibition in Pancreas Cancer
- Amount
- $314K
- Period
- 2008-09-29 → 2011-11-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #7R21CA117125-03
Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer
- Amount
- $246K
- Period
- 2007-12-24 → 2011-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #5K23CA115500-05
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer
- Amount
- $138K
- Period
- 2005-09-12 → 2010-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #5K23CA115500-04
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer
- Amount
- $138K
- Period
- 2005-09-12 → 2010-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #1R21CA135622-01
Evaluation of Src Inhibition in Pancreas Cancer
- Amount
- $296K
- Period
- 2008-09-29 → 2010-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #7K23CA115500-03
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer
- Amount
- $138K
- Period
- 2005-09-12 → 2010-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF COLORADO DENVER
NIH #1K23CA115500-01
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer
- Amount
- $140K
- Period
- 2005-09-12 → 2010-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at JOHNS HOPKINS UNIVERSITY
NIH #1R21CA117125-01A1
Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer
- Amount
- $290K
- Period
- 2006-06-06 → 2008-05-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at JOHNS HOPKINS UNIVERSITY
NIH #5M01RR000052-46
BAY 43-9006 IN COMBINATION WITH CETUXIMAB AND IRINOTECAN
- Amount
- $0K
- Period
- 2006-12-01 → 2007-09-16
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at JOHNS HOPKINS UNIVERSITY
NIH #5R21CA117125-02
Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer
- Amount
- $36K
- Period
- 2006-06-06 → 2007-08-15
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at JOHNS HOPKINS UNIVERSITY
NIH #5K23CA115500-02
Evaluation of Oral EGFR Inhibitors in Colorectal Cancer
- Amount
- $140K
- Period
- 2005-09-12 → 2007-08-15
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at JOHNS HOPKINS UNIVERSITY